 |
UroToday / GU Onc Today invites you to share in exclusive coverage at the upcoming ASCO GU 2022, focused on expert, multidisciplinary perspectives on the latest clinical and scientific advances in the field of GU Oncology. The coverage will include the multi-professional platform for oncology, education and exchange while supporting ASCO GU's immense international visibility for scientific research.
Visit UroToday ASCO GU Sign Up to receive access to invaluable clinical data written by uro-oncologists and medical oncologists. |
|
|
| Anticipated Data from Transformative Trials at ASCO GU 2022 |
Alicia Morgans, MD, MPH and Oliver Sartor, MD
Alicia Morgans and Oliver Sartor discuss the upcoming American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium on Feb 17-20, 2022, and the data from key presentations in prostate cancer, bladder cancer, and kidney cancer. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Sessions of Interest for the Upcoming 2022 Annual Meeting |
|
|
|
|
|
| Novel Treatment Implementation: Prostate-Specific Membrane Antigen Targeting and Beyond |
| 10:00 AM – 11:00 AM EST |
|
|
|
|
Beyond Prostate-Specific Membrane Antigen: New Targets in Prostate Cancer
Presented By: Tanya B. Dorff, MD
|
|
|
|
|
Mechanisms of Resistance to Radiopharmaceuticals
Presented By: Johannes Czernin, MD
|
|
|
|
|
Biomarker Testing in the Era of Novel Therapeutics
Presented By: Himisha Beltran, MD
|
|
|
|
|
|
|
| Oral Abstract Session A: Prostate Cancer |
| 4:00 PM – 5:30 PM EST |
|
|
|
|
PROpel: Phase III Trial of Olaparib and Abiraterone Versus Placebo and Abi as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer
Presented By: Fred Saad, FRCS, MD
Phase 3 MAGNITUDE Study: First Results of Niraparib with Abiraterone Acetate and Prednisone as First-Line Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with and Without Homologous Recombination Repair Gene Alterations
Presented By: Kim N. Chi, MD, FRCPC
|
|
|
|
|
|
|
|
|
|
Overall Survival with Darolutamide Versus Placebo in Combination with Androgen-Deprivation Therapy and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer in the Phase 3 ARASENS Trial.
Presented By: Matthew Raymond Smith, Ph.D., MD
|
|
|
|
|
|
|
| Evolution of Multidisciplinary Management Across the Spectrum of Prostate Cancer |
| 6:00 PM – 7:30 PM EST |
|
|
|
|
Detection Rate of 18F-rhPSMA-7.3 PET in Patients with Suspected Prostate Cancer Recurrence: Results from a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
Presented By: David M. Schuster, MD
|
|
|
|
|
|
|
|
|
| Keynote Lecture
|
| 1:00 - 1:45 PM EST
|
|
|
|
|
A Path Forward: Addressing Disparities in Genitourinary Cancers
Presented By: Karen E. Knudsen, PhD, MBA
|
|
|
|
|
|
| Oral Abstract Session B: Urothelial Carcinoma |
| 3:30 PM – 5:00 PM EST |
|
|
|
|
TROPHY-U-01 Cohort 3: Sacituzumab Govitecan in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cancer Who Progressed After Platinum-Based Regimens
Presented By: Petros Grivas, MD, Ph.D.
|
|
|
|
|
A Randomized, Double Blind, Biomarker Selected, Phase II Clinical Trial of Maintenance PARP Inhibition Following Chemotherapy for Metastatic Urothelial Carcinoma: Final Analysis of the ATLANTIS Rucaparib Arm
Presented By: Simon J. Crabb, Ph.D., MBBS
|
|
|
|
|
BAYOU: A Phase II, Randomized, Multicenter, Double-Blind, Study of Durvalumab in Combination with Olaparib for the First-Line Treatment of Platinum-Ineligible Patients with Unresectable, Stage IV Urothelial Carcinoma
Presented By: Jonathan E. Rosenberg, MD
|
|
|
|
|
|
|
|
| Oral Abstract Session C: Renal Cell Cancer and Rare Tumors |
| 5:00 PM – 6:30 PM EST |
|
|
|
|
Clinical Results of PERICLES: A Phase II Trial Investigating Atezolizumab +/- Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis
Presented By: Hielke Martijn de Vries, MD
|
|
|
|
|
First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients: The ADIUVO Study
Presented By: Alfredo Berruti
|
|
|
|
|
Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Avelumab/axitinib in Patients with Localized Renal Cell Carcinoma Who Are at High Risk of Relapse After Nephrectomy
Presented By: Axel Bex, MD, Ph.D.
|
|
|
|
|
Pembrolizumab as Post Nephrectomy Adjuvant Therapy for Patients with Renal Cell Carcinoma: Results from 30-Month Follow-up of KEYNOTE-564
Presented By: Toni K. Choueiri, MD
|
|
|
|
|
|
|
